Vaxcyte, Inc.

NasdaqGS:PCVX Stock Report

Market Cap: US$7.7b

Vaxcyte Management

Management criteria checks 3/4

Vaxcyte's CEO is Grant Pickering, appointed in Nov 2013, has a tenure of 12.5 years. total yearly compensation is $14.46M, comprised of 5.5% salary and 94.5% bonuses, including company stock and options. directly owns 0.42% of the company’s shares, worth $32.04M. The average tenure of the management team and the board of directors is 4.3 years and 5.4 years respectively.

Key information

Grant Pickering

Chief executive officer

US$14.5m

Total compensation

CEO salary percentage5.53%
CEO tenure12.5yrs
CEO ownership0.4%
Management average tenure4.3yrs
Board average tenure5.4yrs

Recent management updates

Recent updates

Seeking Alpha • May 02

Vaxcyte's Manufacturing-Backed Vaccine Platform Is Redefining The PCV Market

Summary Vaxcyte is evolving from a single-product biotech into a commercial vaccine platform with advanced manufacturing and regulatory alignment. VAX-31, a 31-valent pneumococcal conjugate vaccine, targets broader serotype coverage than competitors and is in pivotal Phase 3 adult and Phase 2 infant trials. PCVX boasts strong financials, with over $2.4B in cash and a completed manufacturing facility, enabling concurrent late-stage development and commercial preparation. Key catalysts include the OPUS-1 Phase 3 readout in Q4 2026, with further adult and infant data in 2027, positioning PCVX as a next-generation vaccine leader. Read the full article on Seeking Alpha
New Narrative • Mar 19

Future Late Stage Vaccine Programs And Manufacturing Capacity Will Drive Long Term Opportunity

Catalysts About Vaxcyte Vaxcyte is a vaccine company focused on developing broader-coverage pneumococcal and Group A Strep vaccines for adult and pediatric use. What are the underlying business or industry changes driving this perspective?
New Narrative • Mar 05

Late Stage Vaccine Programs And New Manufacturing Capacity Will Underpin Long Term Upside

Catalysts About Vaxcyte Vaxcyte is a vaccine company focused on pneumococcal conjugate vaccines and a Group A Strep program, using a carrier sparing platform to target broad disease coverage. What are the underlying business or industry changes driving this perspective?
New Narrative • Mar 03

Late Stage Vaccine Trials And Manufacturing Buildout Will Shape Balanced Long Term Outlook

Catalysts About Vaxcyte Vaxcyte is a vaccine company developing pneumococcal conjugate vaccines and a Group A Strep candidate using a carrier sparing platform and large scale manufacturing infrastructure. What are the underlying business or industry changes driving this perspective?
Analysis Article • Jul 07

We're Not Very Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Mar 31

Vaxcyte: Plunge On FDA Top Regulator Resigning Generates Buying Opportunity

Summary Vaxcyte, Inc.'s positive results achieved from phase 2 dose-finding study using VAX-24 for the prevention of invasive pneumococcal disease in infants; Further post 4 dose data expected 2nd of 2025. It is expected that the 7 major pneumococcal disease markets are to reach a value of $11.6 billion by 2035. VAX-24 goes beyond that of Prevnar 20 in terms of targeting 4 more serotypes than it. PCVX is attempting to expand its program in the prevention of IPD with candidates VAX-31 and VAX-XL; The goal is broaden the disease that can be targeted. Read the full article on Seeking Alpha
Seeking Alpha • Jan 15

Vaxcyte Aims To Outshine Pfizer With Bold VAX-31 Strategy

Summary Vaxcyte's stock surged 68% since August 2023, driven by progress with its pneumococcal conjugate vaccine candidates, VAX-24 and VAX-31. VAX-31, covering 95.6% of serotypes, has been selected over VAX-24 for Phase 3 trials, with topline data expected in 2026. Vaxcyte's robust financial position, with over $3 billion in cash and investments, supports its strategic flexibility and extended timelines. The expanded market guidelines and projected PCV market growth to $12 billion bolster Vaxcyte's potential, with VAX-31's NPV estimated at $13.5 billion upon approval. Despite recent weakness, maintaining a buy rating based on upcoming Phase 3 catalyst and strong cash position, though high valuation presents risks. Read the full article on Seeking Alpha
Seeking Alpha • Sep 06

Vaxcyte: Stunning PCV Data Readout Suggests Vaccine Maker Is A Strong Buy

Summary Vaxcyte's stock surged this week due to promising Phase 1/2 data for its VAX-31 vaccine, showing superior immune responses compared to Pfizer's Prevnar 20. VAX-31 targets 31 strains, covering over 95% of IPD in U.S. adults, with Phase 3 trials expected to deliver top line data by mid-2026. Despite competition from Merck and GSK, Vaxcyte's innovative XpressCF platform offers a significant competitive edge in the growing PCV market. Investors should consider potential risks and wait for market stabilization post-fundraising, but the long-term upside remains compelling with possible +75% upside in play, in my view. There are some risks to consider - length of time to potential approval the most prominent - but it's rare to see such a compelling data set when market incumbents are so established. Read the full article on Seeking Alpha

CEO Compensation Analysis

How has Grant Pickering's remuneration changed compared to Vaxcyte's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$947m

Dec 31 2025US$14mUS$800k

-US$767m

Sep 30 2025n/an/a

-US$657m

Jun 30 2025n/an/a

-US$547m

Mar 31 2025n/an/a

-US$510m

Dec 31 2024US$40mUS$700k

-US$464m

Sep 30 2024n/an/a

-US$508m

Jun 30 2024n/an/a

-US$497m

Mar 31 2024n/an/a

-US$437m

Dec 31 2023US$12mUS$640k

-US$402m

Sep 30 2023n/an/a

-US$300m

Jun 30 2023n/an/a

-US$265m

Mar 31 2023n/an/a

-US$245m

Dec 31 2022US$14mUS$601k

-US$223m

Sep 30 2022n/an/a

-US$174m

Jun 30 2022n/an/a

-US$143m

Mar 31 2022n/an/a

-US$118m

Dec 31 2021US$5mUS$575k

-US$100m

Sep 30 2021n/an/a

-US$92m

Jun 30 2021n/an/a

-US$87m

Mar 31 2021n/an/a

-US$83m

Dec 31 2020US$3mUS$481k

-US$89m

Sep 30 2020n/an/a

-US$83m

Jun 30 2020n/an/a

-US$73m

Mar 31 2020n/an/a

-US$64m

Dec 31 2019US$596kUS$426k

-US$50m

Compensation vs Market: Grant's total compensation ($USD14.46M) is above average for companies of similar size in the US market ($USD8.40M).

Compensation vs Earnings: Grant's compensation has been consistent with company performance over the past year.

CEO

Grant Pickering (57 yo)

12.5yrs
Tenure
US$14,458,937
Compensation

Mr. Grant E. Pickering, M.B.A., is Co-Founder of Vaxcyte, Inc. since 2013 and has been its Chief Executive Officer and Director since November 2013 and served as its President since November 2013 until Dec...

Leadership Team

NamePositionTenureCompensationOwnership
Grant Pickering
Co-Founder12.5yrsUS$14.46m0.42%
$ 32.0m
Andrew Guggenhime
President & CFO6yrsUS$6.07m0.067%
$ 5.1m
James Wassil
Executive VP & COO6.4yrsUS$5.81m0.073%
$ 5.6m
Mikhail Eydelman
Senior VP4.1yrsUS$4.01m0.0087%
$ 668.2k
Harp Dhaliwal
Chief Technical Operations Officer4.5yrsUS$3.76mno data
Jeff Fairman
Co-Founder & VP of Researchno datano datano data
Elvia Cowan
Senior VP of Finance & Chief Accounting Officerno datano data0.0069%
$ 524.3k
Jeff Macdonald
Executive Director of Investor Relationsno datano datano data
Whitney Jones
Chief People Officer2.3yrsno datano data
Janet Graesser
Senior Vice President of Corporate Affairs1.3yrsno datano data
Sam Iki
Senior Vice President of Project Managementno datano datano data
Chris Griffith
Chief Business & Strategy Officerless than a yearno datano data
4.3yrs
Average Tenure
56yo
Average Age

Experienced Management: PCVX's management team is considered experienced (4.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Grant Pickering
Co-Founder12.5yrsUS$14.46m0.42%
$ 32.0m
Annie Drapeau
Independent Director4.7yrsUS$490.51k0.0050%
$ 380.4k
Heath Lukatch
Independent Director8yrsUS$478.01k0.0098%
$ 751.7k
Halley Gilbert
Independent Director6.1yrsUS$490.51k0.0050%
$ 380.4k
Emmanuel Walter
Member of Scientific Advisory Boardno datano datano data
Carlos Paya
Independent Chairman of the Board4.6yrsUS$505.51k0.0050%
$ 380.4k
Anthony Ford-Hutchinson
Member of Scientific Advisory Boardno datano datano data
Jeffrey Almond
Member of Scientific Advisory Board9.3yrsno datano data
Teri Loxam
Independent Director4.7yrsUS$490.51k0.0050%
$ 380.4k
Emmanuel Hanon
Member of Scientific Advisory Boardno datano datano data
William Hausdorff
Member of Scientific Advisory Boardno datano datano data
Jacks Lee
Independent Director2.5yrsUS$480.51k0.0011%
$ 81.9k
5.4yrs
Average Tenure
58yo
Average Age

Experienced Board: PCVX's board of directors are considered experienced (5.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/11 18:26
End of Day Share Price 2026/05/08 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Vaxcyte, Inc. is covered by 15 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason Matthew GerberryBofA Global Research
Thomas ShraderBTIG
Carter GouldCantor Fitzgerald & Co.